One of today's notable stocks in decline is Protalix BioTherapeutics (AMEX:PLX), down 1.5% to $5.82. The Dow Jones Industrial Average is now trading 0.7% higher to 13,877 and the S&P is trading 0.3% higher to 1,493.
Protalix BioTherapeutics Inc. is a biotechnology company that has developed plant cell culture technology and a bioreactor system.
Protalix BioTherapeutics (AMEX:PLX) is currently priced 1.2% above its average consensus analyst price target of $5.75. The stock should find initial support at its 200-day moving average (MA) of $5.55 and further support at its 50-day MA of $5.40.
In the past 52 weeks, shares of Protalix BioTherapeutics have traded between a low of $4.71 and a high of $7.70 and are now at $5.82, which is 24% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 0.3% while the 200-day MA has slid 0.3%.